Loading, Please Wait...
LAS VEGAS, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Dakshidin Corporation’s Whitechapel Holdings Inc. (WCH), a wholly owned subsidiary of Dakshidin Corporation (DKSC) announced today that it has signed a 15-year exclusive worldwide licensing agreement with GenBio, a biotechnology company based in Delaware, USA. The agreement grants WCH exclusive intellectual property, manufacturing and distribution rights worldwide for an entirely new, unique and proprietary product range based on years of clinical research and development.
This new product range is based on WCH’s KDD30™ Formulation, which is a novel “disruptive” platform of new molecules which target specific health and wellness conditions and ailments backed by extensive clinical research. This new element, KDD30™, will be infused into WCH’s proprietary CBD formulas resulting in the only product of its kind on the market worldwide.
The product line will be called “Green Dart” and will consist of a suite of products that will be introduced over the next twelve (12) months;
“We are very excited to bring this unique product to market,” Dakshidin CEO Chris Haigh stated. Mr. Haigh continued, “DKSC will be the first nutraceutical company in the USA to promote and create ‘cutting edge’ health and wellness products that are a combination of existing ingredients that enhance and synergize when paired, giving us a product that is effective and free of any side effects.” A spokesperson for GenBio Inc., also commented, “We will be designing new bespoke products for DKSC based on several novel natural extracts demonstrating phyto activity and synergy in preventing various disease progressions.”
The first Laughing Frogs Green Dart products are expected to be introduced in Q2 of 2019 starting with 30-day daily health packets and a 7-day immune booster pack.
About Dakshidin Corporation (DKSC)
DKSC has positioned itself as an innovator and industry leader in the quickly emerging organic CBD and cannabis-derived health products and services industry. The company is driven by three pillars of thought that guide the development of its business model;
About GenBio Inc.
Based in Delaware, USA, GenBio is a Biotechnology research company that employs a proprietary drug discovery platform to generate novel therapeutic agents for use in multiple and distinct indications. GenBio is developing new nutraceutical products in the fields of pain relief, arthritis, asthma and infectious diseases.
The GenBio disruptive platform of new molecules is aimed at enhancing and synergizing the existing beneficial processes used in the treatment of: Arthritis, Pain relief, Inflammation, MRSA, Obesity, Anti-aging, High blood pressure, UTI, Asthma and Alzheimer’s.
Forward looking statements
The information in this press release includes certain "forward-looking" statements within the meaning of the Safe Harbor provisions of Federal Securities Laws. Investors are cautioned that such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release, and the Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.